Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Q BioMed Inc QBIO

Healthcare Biotechnology
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (GREY:QBIO)

Q BioMed Inc. Provides Update to Shareholders

PR Newswire June 23, 2023

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe

PR Newswire April 14, 2023

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office

PR Newswire February 10, 2023

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.

PR Newswire November 14, 2022

Q BIOMED PROVIDES SHAREHOLDER UPDATE

PR Newswire October 11, 2022

Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER

PR Newswire September 27, 2022

Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.

Accesswire August 25, 2022

Q BioMed Inc. Provides Update to Shareholders

PR Newswire July 29, 2022

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer

PR Newswire July 26, 2022
View More News ››

Opinion & Analysis (GREY:QBIO)

VIDEO: Moving Companies Forward in the BioTechnology Industry

BTV-Business Television July 18, 2016
View More Opinion ››

Bullboard Posts (GREY:QBIO)

The Coronavirus Coping Portfolio (QDEL, GILD, QBIO, CYDY)

The COVID-19 pandemic has forced a dramatic realignment of social, cultural, and economic agendas because, in all cases, the healthcare...
WallstreetPR - May 12, 2020

any good info on this one?

Just read some promotion on Yahoo this morning. Looks like its been churning for years. wondered if anyone had any info on this one...
cashcrab - May 30, 2018
View more Bullboard ››

Mullen Group Ltd.

Mullen Group Ltd.

Mullen Group is one of North America's largest logistics providers with a network of independently operated businesses ...
View More »